SMS Pharma Visakhapatnam facility gets WHO Geneva prequalification

Telangana: SMS Pharmaceuticals Limited has informed in a BSE filing that the company's Unit VII manufacturing facility in Visakhapatnam, Andhra Pradesh, has received prequalification approval from the World Health Organisation (WHO) Geneva.

"This significant milestone enhances our global regulatory standing and enables the company to increase its presence in the global market for Anti-Retroviral (ARV) APIs," SMS Pharma said.

Commenting on this achievement, P. Vamsi Krishna, Executive Director, stated, “The WHO Geneva prequalification reflects the company’s strong compliance with stringent international regulatory standards, reinforcing its reputation for quality, reliability, and global competitiveness."

Read also: Strides Pharma Science Singapore arm secures USFDA nod for nonsteroidal anti-inflammatory drug

Established in 1990, SMS Pharmaceuticals Limited is a diversified and integrated pharmaceutical company specialising in API and intermediatesfor global customers. The Company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag, with capacities of 120 KL and 3,000 KL, respectively.

Read also: SMS Pharma gets one USFDA observation for Bachupally facility